[Artículo traducido] Los inhibidores selectivos de la IL23 son, en su mayoría, efectivos y seguros en pacientes con psoriasis y fallo previo a tratamientos biológicos anti IL-17. Una experiencia de práctica clínica real a 52 semanas / Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience
Actas dermo-sifiliogr. (Ed. impr.)
; 114(4): t363-t365, abr. 2023. tab, graf
Article
in Es
| IBECS
| ID: ibc-219013
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Psoriasis
/
Antibodies, Monoclonal, Humanized
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
Es
Journal:
Actas dermo-sifiliogr. (Ed. impr.)
Year:
2023
Document type:
Article